TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07144852: Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick Plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients With Actinic

Sponsor: Sun Pharmaceutical Industries, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 260 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,220,272

Rescue Site Savings

+$7,401,608

Unlock Full NCT07144852 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07144852 Rescue Dossier →